Clinical Trial Update: Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rituximab for progression of humoral acute rejection after kidney transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Humoral Rejection After Kidney Transplantation
• Kidney Transplant Rejection

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: University Hospital, Tours | Conditions: Humoral Rejection in Kidney Transplantation | Phase 3 | Status: COMPLETED